Dr. Febbo Explains the Oncotype DX Genomic Prostate Score

Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

The Oncotype DX GPS was developed to predict disease aggressiveness to aid in the decision of whether a patient undergoes active surveillance or definitive treatment, says Febbo.

Results from a clinical validation study, conducted in collaboration with Kaiser Permanente Northern California, showed that this test is a strong predictor of biochemical recurrence and rise in prostate-specific antigen (PSA) in patients following surgery.

As of Feburary 2017, 22 clinical trials involving more than 4200 patients with prostate cancer have been conducted.